CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

By M. Todaro, Miriam Gaggianesi, V. Catalano, A. Benfante, F. Iovino, M. Biffoni, Tiziana Apuzzo, I. Sperduti, Silvia Volpe, G. Cocorullo and 4 more. Cell Stem Cell, 2014

700 citations recorded by the source corpus.

Subfields: Hepatology, Oncology, Oral Surgery

View Paper: https://www.semanticscholar.org/paper/28713b172de33f6b5db823981e0f5bc055fbfc10

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Misra
2. R. Markwald
3. S. Ghatak
4. Pengfei Shi
5. H. Cui
6. J. Freeman
7. Zhen Dong
8. Fei Chen

Citations in the corpus

• Targeting cancer stem cell pathways for cancer therapy (2020, background): “[173] [174] [175] In the cytoplasm, TAZ/YAP interacts directly with β-catenin and restricts β-catenin degradation, 176 but TIAM1 antagonizes TAZ/YAP accumulation and translocation from the cytoplasm to the nucleus.”
• Small molecule modulators of pre-mRNA splicing in cancer therapy (2015, background): “CD44v6 was also found to serve as a marker of colorectal cancer stem cells and to be necessary for migration and generation of metastatic colorectal tumors [10].”
• The biology and role of CD44 in cancer progression: therapeutic implications (2018, background): “CD44v6 Migration, metastasis, advanced stage of tumor Colorectal adenocarcinomas [15, 63]”
• Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer (2015, background): “In addition, CD44v6 isoforms are engaged in matrix assembly (384) and have been identified as markers of CSCs in colon cancer, and they account for the metastatic susceptibility of the tumors (385).”